Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT07716280
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Text Messages (TM+) — BEHAVIORAL
    Basic text messages sent directly to the patient's cell phone.
  • Chat bot (CA) — BEHAVIORAL
    Chat bot to answer frequently asked LCS questions.
  • Video — BEHAVIORAL
    Educational video about LCS.
  • Reactive Patient Navigation (RPN) — BEHAVIORAL
    Reactive patient navigation to help get to the LCS appointment.
  • Proactive Patient Navigation (PPN) — BEHAVIORAL
    Proactive patient navigation to help get to the LCS appointment.

Study Details

The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics. LUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages. LUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging/telehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.

Key Dates

First listed
Jul 21, 2026
Start date
Jan 1, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
800 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Other: Stage 1: TM+
    Basic text messages sent directly to the patient's cell phone.
  • Other: Stage 1: TM+, CA
    Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions.
  • Other: Stage 1: TM+, Video
    Basic text messages sent directly to the patient's cell phone. Also includes the option for an educational video about LCS.
  • Other: Stage 1: TM+, CA, Video
    Basic text messages sent directly to the patient's cell phone. Also includes the option for chat bot to answer frequently asked LCS questions and option for educational video about LCS. Patients who complete SDM and are referred to LCS will also be assigned to one of the following conditions. Descriptions of these conditions are as follows:
  • Other: Stage 2: TM+, RPN
    Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and reactive patient navigation to help get to the LCS appointment.
  • Other: Stage 2:TM+, PPN
    Patients who complete SDM and are referred to LCS may be assigned to this condition Patients will receive basic text messages and proactive patient navigation to help get to the LCS appointment. Patients who need transportation financial assistance will receive transportation vouchers to help get them to and from their LCS appointment.

Primary Outcome Measure

Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening [ Time Frame: up to 15 weeks after study enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer Institute/ University of UtahSalt Lake CityUtah84112
Indy Li, MS
[email protected]
801-213-5697
Chelsey Schlechter, MPH, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Salt Lake City, UT

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Huntsman Cancer Institute/ University of Utah· Salt Lake City, UT

Related Studies